Suppr超能文献

硬皮病的表观遗传学:整合遗传、种族、年龄和环境因素的影响

Epigenetics of scleroderma: Integrating genetic, ethnic, age, and environmental effects.

作者信息

Ramos Paula S

机构信息

Division of Rheumatology and Immunology, Department of Medicine and Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.

出版信息

J Scleroderma Relat Disord. 2019 Oct;4(3):238-250. doi: 10.1177/2397198319855872. Epub 2019 Jul 3.

Abstract

Scleroderma or systemic sclerosis is thought to result from the interplay between environmental or non-genetic factors in a genetically susceptible individual. Epigenetic modifications are influenced by genetic variation and environmental exposures, and change with chronological age and between populations. Despite progress in identifying genetic, epigenetic, and environmental risk factors, the underlying mechanism of systemic sclerosis remains unclear. Since epigenetics provides the regulatory mechanism linking genetic and non-genetic factors to gene expression, understanding the role of epigenetic regulation in systemic sclerosis will elucidate how these factors interact to cause systemic sclerosis. Among the cell types under tight epigenetic control and susceptible to epigenetic dysregulation, immune cells are critically involved in early pathogenic events in the progression of fibrosis and systemic sclerosis. This review starts by summarizing the changes in DNA methylation, histone modification, and non-coding RNAs associated with systemic sclerosis. It then discusses the role of genetic, ethnic, age, and environmental effects on epigenetic regulation, with a focus on immune system dysregulation. Given the potential of epigenome editing technologies for cell reprogramming and as a therapeutic approach for durable gene regulation, this review concludes with a prospect on epigenetic editing. Although epigenomics in systemic sclerosis is in its infancy, future studies will help elucidate the regulatory mechanisms underpinning systemic sclerosis and inform the design of targeted epigenetic therapies to control its dysregulation.

摘要

硬皮病或系统性硬化症被认为是由环境或非遗传因素在遗传易感性个体中相互作用所致。表观遗传修饰受遗传变异和环境暴露的影响,并随实际年龄和不同人群而变化。尽管在识别遗传、表观遗传和环境风险因素方面取得了进展,但系统性硬化症的潜在机制仍不清楚。由于表观遗传学提供了将遗传和非遗传因素与基因表达联系起来的调控机制,了解表观遗传调控在系统性硬化症中的作用将阐明这些因素如何相互作用导致系统性硬化症。在受到严格表观遗传控制且易发生表观遗传失调的细胞类型中,免疫细胞在纤维化和系统性硬化症进展的早期致病事件中起着关键作用。本综述首先总结与系统性硬化症相关的DNA甲基化、组蛋白修饰和非编码RNA的变化。然后讨论遗传、种族、年龄和环境对表观遗传调控的影响,重点是免疫系统失调。鉴于表观基因组编辑技术在细胞重编程方面的潜力以及作为一种持久基因调控的治疗方法,本综述最后对表观遗传编辑进行了展望。尽管系统性硬化症的表观基因组学尚处于起步阶段,但未来的研究将有助于阐明系统性硬化症的调控机制,并为设计靶向表观遗传疗法以控制其失调提供依据。

相似文献

1
Epigenetics of scleroderma: Integrating genetic, ethnic, age, and environmental effects.
J Scleroderma Relat Disord. 2019 Oct;4(3):238-250. doi: 10.1177/2397198319855872. Epub 2019 Jul 3.
2
Epigenetics and systemic sclerosis.
Semin Immunopathol. 2015 Sep;37(5):453-62. doi: 10.1007/s00281-015-0504-6. Epub 2015 Jul 11.
3
Unfolding the pathogenesis of scleroderma through genomics and epigenomics.
J Autoimmun. 2017 Sep;83:73-94. doi: 10.1016/j.jaut.2017.05.004. Epub 2017 May 16.
4
Epigenetic Control of Scleroderma: Current Knowledge and Future Perspectives.
Curr Rheumatol Rep. 2019 Dec 7;21(12):69. doi: 10.1007/s11926-019-0877-y.
5
Genetic and epigenetic abnormalities in systemic sclerosis.
J Dermatol. 2016 Jan;43(1):10-8. doi: 10.1111/1346-8138.13221.
6
Epigenetics and systemic sclerosis: An answer to disease onset and evolution?
Eur J Rheumatol. 2020 Oct;7(Suppl 3):S147-S156. doi: 10.5152/eurjrheum.2020.19112. Epub 2020 Jul 20.
7
Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases.
Clin Rev Allergy Immunol. 2022 Dec;63(3):447-471. doi: 10.1007/s12016-022-08956-8. Epub 2022 Nov 8.
8
Epigenetic Modifications in the Pathogenesis of Systemic Sclerosis.
Int J Gen Med. 2022 Mar 19;15:3155-3166. doi: 10.2147/IJGM.S356877. eCollection 2022.
9
Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential.
Nat Rev Rheumatol. 2021 Oct;17(10):596-607. doi: 10.1038/s41584-021-00683-2. Epub 2021 Sep 3.
10
[Epigenetics' implication in autism spectrum disorders: A review].
Encephale. 2017 Aug;43(4):374-381. doi: 10.1016/j.encep.2016.07.007. Epub 2016 Sep 28.

引用本文的文献

2
Recent Insights into Cellular and Molecular Mechanisms of Defective Angiogenesis in Systemic Sclerosis.
Biomedicines. 2024 Jun 14;12(6):1331. doi: 10.3390/biomedicines12061331.
3
Recent Insights into the Role of DNA Methylation and Histone Modifications in Systemic Sclerosis: A Scoping Review.
Diagnostics (Basel). 2024 Mar 20;14(6):652. doi: 10.3390/diagnostics14060652.
5
Symptomatic fractures in systemic sclerosis: A case-control study.
J Scleroderma Relat Disord. 2023 Feb;8(1):79-84. doi: 10.1177/23971983221141271. Epub 2022 Dec 8.
7
The contribution of epigenetics to the pathogenesis and gender dimorphism of systemic sclerosis: a comprehensive overview.
Ther Adv Musculoskelet Dis. 2020 May 6;12:1759720X20918456. doi: 10.1177/1759720X20918456. eCollection 2020.

本文引用的文献

1
Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma.
Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3695-3702. doi: 10.1073/pnas.1813006116. Epub 2019 Feb 12.
2
Lnc-ing Trained Immunity to Chromatin Architecture.
Front Cell Dev Biol. 2019 Jan 24;7:2. doi: 10.3389/fcell.2019.00002. eCollection 2019.
4
Systemic sclerosis and exposure to heavy metals.
Autoimmun Rev. 2019 Jan;18(1):62-72. doi: 10.1016/j.autrev.2018.11.001. Epub 2018 Nov 4.
5
New insights into the genetics and epigenetics of systemic sclerosis.
Nat Rev Rheumatol. 2018 Nov;14(11):657-673. doi: 10.1038/s41584-018-0099-0.
6
In vivo epigenome editing and transcriptional modulation using CRISPR technology.
Transgenic Res. 2018 Dec;27(6):489-509. doi: 10.1007/s11248-018-0096-8. Epub 2018 Oct 4.
7
DNA methylation as a transcriptional regulator of the immune system.
Transl Res. 2019 Feb;204:1-18. doi: 10.1016/j.trsl.2018.08.001. Epub 2018 Aug 9.
8
Insights into myofibroblasts and their activation in scleroderma: opportunities for therapy?
Curr Opin Rheumatol. 2018 Nov;30(6):581-587. doi: 10.1097/BOR.0000000000000543.
9
Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts.
Ann Rheum Dis. 2018 Aug;77(8):1208-1218. doi: 10.1136/annrheumdis-2018-213022. Epub 2018 May 14.
10
Epigenetic modulation as a therapy in systemic sclerosis.
Rheumatology (Oxford). 2019 Feb 1;58(2):191-196. doi: 10.1093/rheumatology/key071.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验